Key Highlights
- Julie O’Shaughnessy appointed as Chief Operating Officer of Vivodyne, overseeing business operations and strategic growth.
- Brings extensive leadership experience from Resilience, AWS, and investment banking sectors.
- Focused on advancing drug discovery and development using Vivodyne’s innovative platform of lab-grown human organs.
Source: Business Wire
Notable Quotes
- “Julie has been instrumental in Vivodyne’s growth and has also been the driving force behind our critical operations and talent acquisition at the highest level — and an incredible part of our team,” – Andrei Georgescu, Ph.D., CEO & Co-Founder at Vivodyne
- “The mission and innovative technology is what drew me to Vivodyne and I’ve been extremely impressed with what our team has been able to achieve in such a short period — I am very excited to help take Vivodyne to the next level,” – Julie O’Shaughnessy, COO at Vivodyne
SoHC's Take
Julie O’Shaughnessy’s appointment as COO of Vivodyne marks a significant step for the company as it continues to pioneer in the realm of drug discovery through lab-grown human tissues. Her robust background in business operations and strategic planning across various major companies positions her uniquely to lead Vivodyne through its next phases of growth and innovation. With a track record of effective leadership and strategic growth, O’Shaughnessy is expected to further enhance Vivodyne’s capabilities in developing lifesaving therapeutics more efficiently and at scale. This strategic move aligns with Vivodyne’s goal to revolutionize the preclinical and clinical development landscape, presenting a promising outlook for the future of therapeutic development.
